Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) FCF Margin (2018 - 2025)

10x Genomics (TXG) has disclosed FCF Margin for 8 consecutive years, with 24.51% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 2356.0% to 24.51% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 21.13% through Dec 2025, up 2026.0% year-over-year, with the annual reading at 21.13% for FY2025, 2026.0% up from the prior year.
  • FCF Margin hit 24.51% in Q4 2025 for 10x Genomics, down from 29.11% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 43.54% in Q4 2021 to a low of 73.71% in Q3 2021.
  • Historically, FCF Margin has averaged 5.98% across 5 years, with a median of 3.94% in 2021.
  • Biggest five-year swings in FCF Margin: skyrocketed 14956bps in 2021 and later tumbled -10028bps in 2022.
  • Year by year, FCF Margin stood at 43.54% in 2021, then crashed by -230bps to 56.74% in 2022, then surged by 121bps to 12.13% in 2023, then plummeted by -92bps to 0.96% in 2024, then soared by 2463bps to 24.51% in 2025.
  • Business Quant data shows FCF Margin for TXG at 24.51% in Q4 2025, 29.11% in Q3 2025, and 11.16% in Q2 2025.